Page 6 - Houng Kim News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Celltrion Healthcare receives European Commission (EC) approval for the first high concentration, low-volume and citrate-free biosimilar adalimumab, YuflymaTM (CT-P17)
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Celltrion s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation-財經新聞-新浪新聞中心
sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
for those of you looking to catch-up on biosimilars in 2020 and what these experts are most excited about for the year(s) ahead. As the Editorial Board explores which challenges are ahead for 2021, it’s reassuring to note that sustainability is increasingly entering the U.S. biosimilars conversation. As you’ll note in this installment, there are several particularly passionate calls-to-action for companies to confront misinformation, collaborate with stakeholders, and to refine their commercial business models in the name of greater market efficiency. Though there is a lot to be done, it’s clear from these answers that stakeholders are relying more heavily on biosimilars and that it’s more important than ever for biosimilar companies to keep carrying the torch for more competition, cost-savings, value, and responsible pricing.
Celltrion Healthcare: Celltrion Group meldet positive Wirksamkeits- und Sicherheitsdaten aus der globalen klinischen Phase-II/III-Studie mit dem COVID-19-Behandlungskandidaten CT-P59
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Celltrion’s investigational mAb cuts COVID-19 recovery time
Patients treated with mAb recovered 3.4 to 6.4 days quicker compared to placebo
South Korean-based Celltrion has posted positive data for its investigational COVID-19 targeting monoclonal antibody (mAb) from a phase 2/3 study.
The first portion of the phase 2/3 study of the mAb, CT-P59, enrolled 327 patients with mild-to-moderate symptoms of COVID-19 across three treatment groups.
Participants were randomised to receive either CT-P59 40 mg/kg, CT-P59 80mg/kg or placebo.
Within this patient population, approximately 60% of patients with moderate symptoms also suffered from COVID-19-related pneumonia.
At day 28, patients treated with Celltrion’s mAb demonstrated a significantly reduced risk of COVID-19 related hospitalisation and oxygenation without mortality.